Vaxcyte director receives RSUs and stock options

Vaxcyte director Olivier Brandicourt received new equity awards consisting of restricted stock units (RSUs) and stock options.

Rhea-AI Filing Summary

Vaxcyte director Olivier Brandicourt received new equity awards consisting of restricted stock units (RSUs) and stock options. He was granted 2,194 RSUs, each representing one share of Vaxcyte common stock. These RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to his continuous service.

He also received stock options for 11,034 shares of common stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These options vest monthly and will be fully vested on the same earlier-of-2027-or-next-meeting schedule. Following the RSU grant, he directly holds 4,699 common shares.

Insider Trade Summary

Grant/Award: 13,228 shares

Grant/Award 2 txns

Insider BRANDICOURT OLIVIER

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	11,034	$0.00	$0.00
Grant/Award	Common Stock	2,194	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 11,034 contracts (Direct); Common Stock — 4,699 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
2. F2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Key Figures

RSU grant: 2,194 shares Option grant size: 11,034 shares Option exercise price: $49.56 per share +2 more

5 metrics

RSU grant 2,194 shares Restricted stock units awarded to director on June 15, 2026

Option grant size 11,034 shares Stock options granted on June 15, 2026

Option exercise price $49.56 per share Strike price for 11,034 stock options

Option expiration June 15, 2036 Expiry date of granted stock options

Shares held after grant 4,699 shares Total direct common stock holdings after RSU award

Key Terms

restricted stock units ("RSUs"), contingent right, vest, exercise price, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents the contingent right to receive one share of the Issuer's Common Stock."

vest financial

"The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"subject to the Reporting Person's continuous service through such date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Vaxcyte (PCVX) director Olivier Brandicourt report?

Olivier Brandicourt reported equity compensation grants from Vaxcyte, including restricted stock units and stock options. The filing shows no open-market buying or selling, only awards that increase his potential ownership if service and vesting conditions are met.

How many restricted stock units did Olivier Brandicourt receive from Vaxcyte (PCVX)?

He received 2,194 restricted stock units (RSUs), each tied to one Vaxcyte common share. These RSUs vest in full on the earlier of June 15, 2027 or the day before the next annual meeting, assuming his continuous service with the company.

What are the terms of Olivier Brandicourt’s new Vaxcyte (PCVX) stock options?

He was granted options on 11,034 shares of Vaxcyte common stock at an exercise price of $49.56 per share. The options vest monthly and fully vest by the earlier of June 15, 2027 or the day before the next annual meeting, and expire June 15, 2036.

Did Olivier Brandicourt buy or sell Vaxcyte (PCVX) shares on the market in this Form 4?

The Form 4 shows no open-market purchases or sales by Olivier Brandicourt. It reports only equity awards classified as grants or other acquisitions, which are compensation-related rather than discretionary trading in Vaxcyte’s stock.

How many Vaxcyte (PCVX) common shares does Olivier Brandicourt hold after these grants?

After the reported RSU grant, Olivier Brandicourt directly holds 4,699 shares of Vaxcyte common stock. This figure reflects his direct non-derivative holdings and does not include unvested RSUs or unexercised stock options reported in the same filing.

When will Olivier Brandicourt’s Vaxcyte (PCVX) RSUs and options be fully vested?

Both the 2,194 RSUs and the 11,034 stock options are designed to fully vest by the earlier of June 15, 2027 or the day prior to Vaxcyte’s next annual stockholder meeting, provided Olivier Brandicourt maintains continuous service with the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRANDICOURT OLIVIER

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		A		2,194(1)	A	$0	4,699	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$49.56	06/15/2026		A		11,034		(2)	06/15/2036	Common Stock	11,034	$0	11,034	D

Explanation of Responses:

1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Remarks:

	Olivier Brandicourt, by /s/ Peter N. Efremenko, Attorney-In-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)